Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Carisma Therapeutics Inc (Carisma Therapeutics), formerly Sesen Bio Inc, is a biotechnology company that carries out the development of innovative cellular therapies for the treatment of cancer and other serious disorders. The company's main activities involve leveraging the natural power of monocytes and macrophages, engineering them to attack tumors through their CAR-Macrophages (chimeric antigen receptor macrophages) technology. Carisma's major products include CAR-Macrophages and CAR-Monocytes, which are designed to target solid tumors by engineering a patient’s own immune cells. The company's therapies are intended for patients with cancer, particularly those with solid tumors. It operates in the US, the UK, and Canada. Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania, the US.
Headquarters
United States of America
Address
Suite 401, 3675 Market Street, Philadelphia, Pennsylvania, 19104
Website
sesenbio.com
Telephone
1 302 6587581
No of Employees
46
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CARM (OTC)
Revenue (2023)
$19.6M
31.6%
(2023 vs 2022)
EPS
XYZ
Net Income (2023)
XYZ
30.4%
(2023 vs 2022)
Market Cap*
$240,000
Net Profit Margin (2023)
XYZ
47.1%
(2023 vs 2022)
* As of and is in US$
Carisma Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipelines: |
| CT – 0525 (CAR-Monoctye) |
| CT – 0508 (CAR-Macrophage) |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In June, the company signed an agreement to merge with OrthoCellix Inc. |
| 2023 | Acquisitions/Mergers/Takeovers | In March, the company merged with Carisma Therapeutics Inc. |
| 2021 | Contracts/Agreements | In August, the company entered into a licensing agreement for the registration and commercialization of Vicineum to treat patient with BCG-unresponsive non-muscle invasive bladder cancer. |
Competitor Comparison
| Key Parameters | Carisma Therapeutics Inc | Eli Lilly and Co | Merck & Co Inc | Bristol-Myers Squibb Co | Amgen Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Philadelphia | Indianapolis | Rahway | Princeton | Thousand Oaks |
| State/Province | Pennsylvania | Indiana | New Jersey | New Jersey | California |
| No. of Employees | 46 | 50,605 | 75,000 | 32,500 | 31,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Sanford Zweifach | Chairman | Executive Board | - | 69 |
| Eugene P. Kennedy M.D | Chief Medical Officer | Senior Management | 2024 | - |
| Tom Wilton | Chief Business Officer | Senior Management | - | - |
| Eric Siegel | Secretary; General Counsel | Senior Management | - | - |
| Kenneth Locke | Senior Vice President - Technical Operations | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer